Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $47.25

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given an average rating of “Buy” by the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $47.25.

A number of research analysts have recently weighed in on IMUX shares. Roth Capital reissued a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Immunic in a report on Thursday, September 10th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Immunic in a research note on Thursday, September 10th. Finally, Wall Street Zen raised Immunic from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Institutional Trading of Immunic

Hedge funds have recently modified their holdings of the company. Braidwell LP bought a new position in Immunic during the 2nd quarter worth approximately $9,914,000. Avidity Partners Management LP raised its holdings in Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after purchasing an additional 2,000,000 shares during the period. CTC Alternative Strategies Ltd. acquired a new stake in Immunic in the first quarter worth $27,000. Bank of America Corp DE raised its holdings in Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after purchasing an additional 143,689 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in shares of Immunic during the first quarter worth $33,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Price Performance

IMUX opened at $10.64 on Monday. The company has a market cap of $145.12 million, a price-to-earnings ratio of -2.43 and a beta of 1.41. The firm has a 50 day simple moving average of $14.25 and a 200 day simple moving average of $13.14. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $17.43.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, analysts expect that Immunic will post -3.71 EPS for the current year.

Immunic Company Profile

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for chronic inflammatory and neurodegenerative diseases. The company’s research programs are designed to address conditions affecting the immune system and central nervous system, including multiple sclerosis and selected gastrointestinal disorders.

Immunic’s lead investigational product is vidofludimus calcium, also known as IMU-838, a selective oral inhibitor of the enzyme dihydroorotate dehydrogenase.